Global Journal of Medical Research, A: Neurology & Nervous System, Volume 23 Issue 3

11. Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry. 2000; 61 Suppl 6: 7-11. 12. Hirschfeld R. History and evolution of the monoamine hypothesis of depression. Journal of Clinical Psychiatry 2000; 61 (6): 4-6. 13. Neumeister A, Nugent AC, Waldeck T, et al. Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry 2004; 61: 765-773. 14. El-Mallakh RS, Vöhringer PA, Ostacher MM, et al. Antidepressants worsen rapid-cycling course in bipolar depression: A STEP-BD randomized clinical trial. Journal of Affective Disorders 2015; 184: 318-321. 15. Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disorders 2001; 5 (6). 16. Truman CJ, Goldberg JF, Ghaemi SN. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry 2007; 68 (10): 1472-1479. 17. Henry C, Sorbara F, Lacoste J, Gindre C, Leboyer M. Antidepressant-induced mania in bipolar patients: Identification of risk factors. J Clin Psychiatry 2001; 62 (4): 249-255. 18. Yamaguchi Y, Kimoto S, Nagahama T, Kishimoto T. Dosage-related nature of escitalopram treatment- emergent mania/hypomania: a case series. Neuropsychiatr Dis Treat 2018; 14: 2099-2104. 19. Binder MR. Mind-brain dynamics in the pathophysiology of psychiatric disorders. Am J Psychiatry and Neurosci 2022; 10 (2): 48-62. 20. Binder MR. The multi-circuit neuronal hyperexcitability hypothesis of psychiatric disorders. AJCEM 2019; 7 (1): 12-30. 21. Binder MR. Probing the link between substance use and psychiatric disorders: Toward a new paradigm in the treatment and prevention of these intertwined disorders. Int J Psychiatry Res 2023; 6 (3): 1-13. 22. Binder MR. The neuronal excitability spectrum: A new paradigm in the diagnosis, treatment, and prevention of mental illness and its relation to chronic disease. AJCEM 2022; 10 (1): 1-7. 23. Binder MR. Electrophysiology of seizure disorders may hold key to the pathophysiology of psychiatric disorders. AJCEM 2019; 7 (5): 103-110. 24. Binder MR. Neuronal hyperexcitability: Significance, cause, and diversity of clinical expression. AJCEM 2021; 9 (5); 157-167. 25. Binder MR. FLASH syndrome: Tapping into the root of chronic illness. AJCEM 2020; 8 (6): 101-109. 26. Binder MR. Suicide: A new hypothesis on the pathogenesis of disease, method of screening, and means of prevention. AJPN 2022; 10 (3): 111-124. 27. Binder MR. Neuronal hyperexcitability: The elusive link between social dysfunction and biological dysfunction. World J Public Health 2022; 7 (3): 99-110. 28. Binder MR. Anticonvulsants: The psychotropic and medically protective drugs of the future. AJCEM 2021; 9 (5): 174-182. 29. Binder MR. Illicit use of gabapentin may reveal more about the drug’s benefits than its liabilities. American J Int Med 2022; 10 (6): 114-121. 30. Post RM, Denicoff KD, Frye MA, et al. A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th century. Neuropsychobiology 1998; 38 (3): 152-166. 31. Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016; 30 (6): 495-553. 32. Shah B, Elsayed OH, El-Mallakh RS. Bipolar disorder: The foundational role of mood stabilizers. Current Psychiatry 2023; 22 (5): 36-41. 33. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63 (8): 856-864. 34. Newport DJ, Carpenter LL, McDonald WM, et al. APA Council of Research Task Force on Novel Biomarkers and Treatments. Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression. Am J Psychiatry 2015; 172 (10): 950-966. 35. Gunduz-Bruce H, Silber C, Kaul I, et al. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med2019; 381 (10): 903-911. 36. Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. Effect of zuranolone vs placebo in postpartum depression: A randomized clinical trial. JAMA Psychiatry 2021; 78 (9): 951-959. 37. Zorumski CF, Paul SM, Covey DF, Mennerick S. Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond. Neurobiology of Stress 2019; 11: 100196. 38. Kreston R. (2016) The psychic energizer! the serendipitous discovery of the first antidepressant - Body Horrors. http://blogs.discovermagazine.com/ bodyhorrors/2016/01/27/2 081/. (Accessed 10/2/18). 39. Cuellar AK, Johnson SL, Winters R. Distinctions between bipolar and unipolar depression. Clin Psychol Rev 2005; 25 (3): 307-339. 40. Ghaemi SN. Bipolar spectrum: a review of the concept and a vision for the future. Psychiatry Investig 2013; 10 (3): 218-224. 32 Year 2023 Global Journal of Medical Research Volume XXIII Issue III Version I ( D ) A © 2023 Global Journals A Precision Medicine Approach to the Treatment of Psychiatric Disorders